A judge has ruled against investor Alcon Research on the matter of blocking investee Aurion Biotech from debuting on the ...

Cell therapy company Aurion Biotech is moving forward with plans to IPO despite a pending lawsuit from one of its existing ...

Alcon Research LLC lost its court bid Tuesday to veto a public listing by Aurion Biotech Inc., a business it’s backing, but ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

A Delaware judge issued a split ruling in a bizarre legal squabble over the IPO plans of Aurion Biotech, which should allow ...

Investors typically celebrate IPOs as milestone moments — and potential exit opportunities — for their startups. In an ...

In this Healio Video Perspective from Hawaiian Eye 2025, Greg Kunst, CEO of Aurion Biotech, discusses positive phase 1/2 data ...

Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tissue.

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion Biotech), whose mission is to restore vision to millions of patients with life-changing regenerative therapies ...

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...

Detailed price information for Aurion Resources Ltd (AU-X) from The Globe and Mail including charting and trades.